INTRODUCTION
Several epidemiological studies showed an increased risk of many types of cancer in type 2 diabetic or obese patients [1] [2] [3] [4] . On the basis of a meta-analysis of 15 studies performed in the years 1966-2005 with over 2.5 million participants, Larsson et al. [5] showed a relationship between type 2 diabetes and an increased risk of colorectal cancer, both in men and women. Other investigatos highlighted the coexistence of type 1 diabetes and colorectal cancer [3] . Importance of hyperglycemia and hyperinsulinemia in cancerogenesis and the coexistence of these disorders in patients with colorectal cancer were stressed in a number of studies [6] [7] [8] .
Uterine, prostate and breast cancer are also related to metabolic disorders [9] [10] [11] [12] . Among the environmental factors asso-ciated with an increased risk of colorectal cancer is a high-calorie diet with excessive fats and fiber deficiency. Fat stimulates the secretion of bile acids, which are transformed by intestinal bacteria into secondary and tertiary acids. These, in turn, may cause mutation in intestinal epithelial cells. On the other hand, fiber deficiency impairs the intestinal passage, which increases the exposition of intestinal cells to cancerogens present in the intestinal contents [6] . Insulin and insulin-like growth factor-1 (IGF1) are factors for diet-dependent cancers [3, [13] [14] [15] . Insulin can be characterized by intracellular, pleiotropic action, associated on the one hand with metabolic effects -the metabolism of glucose, proteins and lipids, and on the other hand with growth-promoting effects, the proliferation of cells, and their influence on apoptosis and the cellular cycle [16] . The growth factor effect, which promotes tumor development, is reported during high levels of this hormone. The mitogenic influence of insulin can be reported as a result of binding with the insulin-like growth factor-1 receptor (IGF1R) -the autophosphorylation of this receptor is of key importance in the generation of growth and proliferation-related signals [3, 14, 17] .
The aim of this study was to analyze serum insulin levels in patients with adenocarcinoma of the colon, depending on the ad- 
Insulin level assay
The insulin serum level was assayed with the ELISA method, with the use of BioSource INS-EASIA Kit set (catalogue number KAP1251) by the BioSource Europe S.A. (Belgium) according to the manufacturer's instructions. Absorption was taken with the ELISA reader (PowerVave XS, Biotek, USA) at a wavelength of 450 nm. The substance level value was read from the curve for insulin level patterns and expressed in µlU/ml. Measurements were made in duplicates. The variability percentage between samples varied from 3.1 to 9.6%. The average method sensitivity was 0.15 µlU/ml.
Selected data for epidemiological evaluation were transferred onto the calculation sheet using the MS Excel program. A statistical analysis was performed to outline the structure of the group of patients analyzed. Frequency tables were used to analyze qualitative data. The quantitative data obtained were evaluated with the use of distribution parameters. In addition, the ANOVA one-criterion analysis was used. Values of p ≤0.05 were considered statistically significant.
RESULTS
In a group of 70 patients, obesity was diagnosed (BMI >30 kg/m 2 ) in 10 patients (14.29%), 31 patients (44.29%) were overweight (BMI 25-30 kg/m 2 ) and 29 patients (41.43%), had normal weight (Tab. 1). One patient was reported to be underweight (BMI 18.18 kg/m²), and was included into the normal weight group. In 5 patients, in the final months of observation, a less than 10% decrease in body mass was reported. In the majority of patients (n = 50, 71.43%) normal blood serum glucose levels (3.61-5.83 mmol/l) were noted. Incorrect fasting glucose (5.83-6.9 mmol/l) was observed in 16 patients (22.85%). The average BMI value for the whole group was 25.98 ±5.38 kg/m². The mean glucose serum level was 5.49 ±1.0 mmol/l and the average insulin level was within the normal range (626 µlM/ml), at 18.93 ±14.67 µlM/ml. The following phase of analysis was to search for differences in the obtained quantitative data, depending on the clinical grade (Tab. 2). No statistically significant differences between groups were reported with regard to the clinical grade. Higher insulin level (25.65 ±21.14 µlM/ml) was reported only in the group of patients in the 3rd clinical grade. In patients in the 1st clinical grade, insulin levels were 13.96 ±3.25 µlM/ml, in the 2nd grade 15.90 ±9.72 µlM/ml, and in the 4th grade 17.89 ±12.37 µlM/ml.
In terms of weight categories, no significant statistical differences in the analysis of average glucose and insulin levels were reported according to BMI values (Fig. 1 ). There were no significant differences between the average BMI, glucose and insulin serum levels in relation to tumor localization (Fig. 2-4) . vancement of the clinical stage, a degree to which the patient is overweight or obese, and the localization of tumor.
PATIENTS AND METHODS
The study was performed among 70 patients (41 men and 29 women) with established diagnosis of adenocarcinoma of the colon. The patient average age was 65 years. Coexistent diseases were considered during the patient selection. Patients suffering from diabetes, other cancers and using hormonal medications were excluded from the research group. Tumors were localized in 39 patients (55.71%) in the colon and the sigmoid colon, in 31 patients (44.29%) in the rectum. Selected data from the medical documentation of patients were analyzed. Qualitative variables, i.e. sex, the clinical grade of colon adenocarcinoma, weight category and occurrence of cardiovascular diseases were analyzed. The qualitative variables analyzed included the patient's age, body mass index (BMI -kg/m²), fasting glucose (mmol/l) and fasting insulin level (µlU/ml) values in blood serum. Glucose level was routinely examined upon the patient's qualification for surgery and established from the average of 3 measurements. Insulin level assay was additionally performed at the time of routine tests (from one injection from the antecubital vein), after the surgical treatment and before qualification for supplementary (randomized trials, controlled trials or randomized controlled trials), follow-up or palliative treatment. The patients gave an informed consent to the study and additional measurements were made. 
ORIGINAL ARTICLES
On the basis of the current study it can be confirmed that body weight beyond the reference values is reported in several patients with colorectal cancer. Over half the patients were overweight or obese (BMI >25 kg/m 2 ). However, there were no reports of statistically significant differences involving average insulin levels depending on BMI. Higher average fasting insulin levels were reported in patients in the 3rd clinical grade of cancer, but with no significant statistical differences. The study was not performed among healthy subjects; thus
DISCUSSION
The results obtained in the current study should be interpreted with caution. The group of patients who took part in the study was too small and clinically heterogeneous. However, it should be noted that in the majority of analyzed patients too high body mass index was reported, which additionally determines the presence of impaired fasting glucose, insulin resistance, or undiagnosed type 2 diabetes. lin resistance and decreasing hyperinsulinemia, which inhibits the mitogenic action of insulin and insulin-like growth factors by minimizing the role of intracellular signal transduction activated by these factors. We concluded that overweight and obesity were observed in most of the colorectal cancer patients, andno statistical differences were observed between insulin serum level and tumor localization.
